Beam Therapeutics (BEAM) Competitors

Beam Therapeutics logo
$20.94 -1.89 (-8.28%)
Closing price 04:00 PM Eastern
Extended Trading
$21.44 +0.50 (+2.41%)
As of 05:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BEAM vs. CRSP, DNLI, EDIT, NTLA, and PRME

Should you buy Beam Therapeutics stock or one of its competitors? Beam Therapeutics's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and Prime Medicine (PRME). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Beam Therapeutics compare to CRISPR Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and CRISPR Therapeutics (NASDAQ:CRSP) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Beam Therapeutics presently has a consensus price target of $47.64, indicating a potential upside of 108.35%. CRISPR Therapeutics has a consensus price target of $72.93, indicating a potential upside of 72.65%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Beam Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65

Beam Therapeutics has a net margin of -73.04% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Beam Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
CRISPR Therapeutics -1,812.07%-25.59%-17.89%

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Beam Therapeutics had 7 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 24 mentions for Beam Therapeutics and 17 mentions for CRISPR Therapeutics. Beam Therapeutics' average media sentiment score of 0.73 beat CRISPR Therapeutics' score of 0.15 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
CRISPR Therapeutics
2 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Beam Therapeutics has higher revenue and earnings than CRISPR Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A
CRISPR Therapeutics$3.51M1,167.32-$581.60M-$4.74N/A

Beam Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

Summary

Beam Therapeutics beats CRISPR Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Denali Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Denali Therapeutics (NASDAQ:DNLI) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

Beam Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A
Denali Therapeutics$330.53M9.09-$512.54M-$1.73N/A

Beam Therapeutics presently has a consensus price target of $47.64, suggesting a potential upside of 108.35%. Denali Therapeutics has a consensus price target of $35.71, suggesting a potential upside of 90.58%. Given Beam Therapeutics' higher probable upside, equities analysts clearly believe Beam Therapeutics is more favorable than Denali Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
Denali Therapeutics
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Denali Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -73.04%. Beam Therapeutics' return on equity of -32.76% beat Denali Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
Denali Therapeutics N/A -54.94%-42.15%

In the previous week, Beam Therapeutics had 10 more articles in the media than Denali Therapeutics. MarketBeat recorded 24 mentions for Beam Therapeutics and 14 mentions for Denali Therapeutics. Beam Therapeutics' average media sentiment score of 0.73 beat Denali Therapeutics' score of 0.60 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Denali Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Summary

Beam Therapeutics beats Denali Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Beam Therapeutics compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Editas Medicine has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Editas Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Editas Medicine$40.52M8.27-$160.06M-$0.62N/A
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A

In the previous week, Beam Therapeutics had 3 more articles in the media than Editas Medicine. MarketBeat recorded 24 mentions for Beam Therapeutics and 21 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.73 beat Editas Medicine's score of 0.20 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Editas Medicine
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
4 Negative mention(s)
1 Very Negative mention(s)
Neutral
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Beam Therapeutics has a net margin of -73.04% compared to Editas Medicine's net margin of -144.95%. Beam Therapeutics' return on equity of -32.76% beat Editas Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Editas Medicine-144.95% -130.43% -36.45%
Beam Therapeutics -73.04%-32.76%-25.80%

Editas Medicine presently has a consensus target price of $5.83, indicating a potential upside of 168.82%. Beam Therapeutics has a consensus target price of $47.64, indicating a potential upside of 108.35%. Given Editas Medicine's higher probable upside, equities research analysts clearly believe Editas Medicine is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Editas Medicine
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

71.9% of Editas Medicine shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Beam Therapeutics beats Editas Medicine on 14 of the 16 factors compared between the two stocks.

How does Beam Therapeutics compare to Intellia Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Intellia Therapeutics (NASDAQ:NTLA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Beam Therapeutics has a net margin of -73.04% compared to Intellia Therapeutics' net margin of -805.75%. Beam Therapeutics' return on equity of -32.76% beat Intellia Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Beam Therapeutics-73.04% -32.76% -25.80%
Intellia Therapeutics -805.75%-64.74%-50.72%

Beam Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market.

Beam Therapeutics presently has a consensus target price of $47.64, indicating a potential upside of 108.35%. Intellia Therapeutics has a consensus target price of $21.44, indicating a potential upside of 121.08%. Given Intellia Therapeutics' higher probable upside, analysts clearly believe Intellia Therapeutics is more favorable than Beam Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77
Intellia Therapeutics
4 Sell rating(s)
7 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.33

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A
Intellia Therapeutics$67.67M20.12-$412.69M-$3.35N/A

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 3.5% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 4 more articles in the media than Intellia Therapeutics. MarketBeat recorded 24 mentions for Beam Therapeutics and 20 mentions for Intellia Therapeutics. Beam Therapeutics' average media sentiment score of 0.73 beat Intellia Therapeutics' score of -0.06 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Intellia Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 14 factors compared between the two stocks.

How does Beam Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Prime Medicine currently has a consensus price target of $7.86, suggesting a potential upside of 84.01%. Beam Therapeutics has a consensus price target of $47.64, suggesting a potential upside of 108.35%. Given Beam Therapeutics' higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Prime Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prime Medicine
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.89
Beam Therapeutics
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.77

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Beam Therapeutics had 1 more articles in the media than Prime Medicine. MarketBeat recorded 24 mentions for Beam Therapeutics and 23 mentions for Prime Medicine. Beam Therapeutics' average media sentiment score of 0.73 beat Prime Medicine's score of 0.58 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prime Medicine
8 Very Positive mention(s)
1 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
4 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Prime Medicine has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.23, suggesting that its share price is 123% more volatile than the broader market.

Beam Therapeutics has higher revenue and earnings than Prime Medicine. Beam Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prime Medicine$4.63M167.28-$201.14M-$1.06N/A
Beam Therapeutics$146.64M16.14-$79.99M-$1.04N/A

Beam Therapeutics has a net margin of -73.04% compared to Prime Medicine's net margin of -2,497.56%. Beam Therapeutics' return on equity of -32.76% beat Prime Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Prime Medicine-2,497.56% -222.88% -59.68%
Beam Therapeutics -73.04%-32.76%-25.80%

Summary

Beam Therapeutics beats Prime Medicine on 12 of the 15 factors compared between the two stocks.

Get Beam Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BEAM vs. The Competition

MetricBeam TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.17B$4.07B$7.83B$11.75B
Dividend YieldN/A3.64%2.47%4.41%
P/E Ratio-20.1324.2434.3430.11
Price / Sales14.7814.858.005.32
Price / CashN/A21.8921.0222.34
Price / Book1.724.354.763.85
Net Income-$79.99M-$24.19M$3.52B$393.14M
7 Day Performance-22.50%-7.26%-5.34%-4.53%
1 Month Performance-10.78%-4.96%-3.61%-5.86%
1 Year Performance-3.59%-2.87%0.01%-7.78%

Beam Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BEAM
Beam Therapeutics
2.743 of 5 stars
$20.94
-8.3%
$47.64
+127.5%
+5.3%$2.17B$146.64MN/A540
CRSP
CRISPR Therapeutics
2.8475 of 5 stars
$50.04
-0.1%
$69.69
+39.3%
-19.6%$5.02B$3.51MN/A393
DNLI
Denali Therapeutics
3.7644 of 5 stars
$20.33
+1.3%
$36.15
+77.8%
+7.5%$3.36B$330.53MN/A507
EDIT
Editas Medicine
2.3284 of 5 stars
$2.75
+7.0%
$5.83
+112.1%
-16.5%$417.74M$40.52MN/A87
NTLA
Intellia Therapeutics
2.5593 of 5 stars
$12.11
+6.7%
$21.05
+73.8%
+11.5%$1.72B$67.67MN/A377

Related Companies and Tools


This page (NASDAQ:BEAM) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners